Industries > Pharma > Anticoagulants Market Report to 2031
Anticoagulants Market Report to 2031
By Type (Vitamin K Antagonists (VKA), Non-VKA Oral Anticoagulants (Noacs), Heparin, Others), By Application (Atrial Fibrillation, Deep Vein Thrombosis (DVT), Ischemic Stroke, Myocardial Infarction (Heart Attack), Pulmonary Embolism, Others) By Administration (Oral Anticoagulant, Injectable Anticoagulant). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Global Anticoagulants Market– our new study reveals trends, R&D progress, and predicted revenues.
Where is the Global Anticoagulants Market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Global Anticoagulants Market report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Anticoagulants Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Anticoagulants Market by Type
• Vitamin K Antagonists (VKA)
• Non-VKA Oral Anticoagulants (NOACs)
• Heparin
• Others
Anticoagulants Market by Application
• Atrial fibrillation
• Deep vein thrombosis (DVT)
• Ischemic stroke
• Myocardial infarction (heart attack)
• Pulmonary embolism
• Others
Anticoagulants Market by Administration
• Oral anticoagulant
• Injectable anticoagulant
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Anticoagulants Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Anticoagulants Market with forecasts for by Type, by Application and by Administration each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Anticoagulants Market report helps you
In summary, our 240+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Global Anticoagulants Market, with forecasts by type, by application, and by administration, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the global anticoagulants market in North America, Europe, Asia-Pacific, and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Anticoagulants of the major companies involved in the Anticoagulants Market. Some of the company’s profiled in this report include-
• Abbott Laboratories
• Baxter International Inc.
• AstraZeneca plc
• Bayer AG.
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Genentech Inc.
• GlaxoSmithKline plc
• Pfizer, Inc.
• Sanofi S.A
• Novartis AG
• Daiichi Sankyo Company
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global Anticoagulants Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Anticoagulants Market Report to 2031: By Type (Vitamin K Antagonists (VKA), Non-VKA Oral Anticoagulants (Noacs), Heparin, Others), By Application (Atrial Fibrillation, Deep Vein Thrombosis (DVT), Ischemic Stroke, Myocardial Infarction (Heart Attack), Pulmonary Embolism, Others) By Administration (Oral Anticoagulant, Injectable Anticoagulant). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Anticoagulants Market
2.1. Anticoagulants Market Definition
2.2. By Type Submarkets Definitions
2.3. By Application Submarkets Definitions
2.4. By Administration Submarkets Definitions
3. Anticoagulants Market Overview
3.1. Global Anticoagulants Market Size and Forecast by Region
3.2. Global Anticoagulants Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Geriatric Population
3.3.1.2. Rising prevalence of cancer
3.3.1.3. Global Healthcare Expenditure
3.3.1.4. Increasing cardiovascular disease & Diabetic Population.
3.3.1.5. Surging smoking & Obese Population.
3.3.2. Market Restraints/Challenges
3.3.2.1. Complication associated with use of oral anticoagulants.
3.3.2.2. High Cost
3.3.3. Opportunities
3.3.3.1. Increasing investment in R&D
3.3.3.2. Increasing FDA approval of anticoagulants drugs for clinical purpose.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Anticoagulants Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Vitamin K Antagonists (VKA)
4.1.2. VKA are group of substances which reduce the action of vitamin K and blood clotting.
4.1.3. Non-VKA Oral Anticoagulants (NOACs)
4.1.4. Rivaroxaban & fondaparinux works on Factor Xa inhibitor, which affects factor Xa within blood.
4.1.5. Heparin
4.1.6. Low-molecular-weight heparin (LMWH) such as dalteparin, enoxaparin, and tinzaparin, are given through subcutaneous injections.
4.1.7. others
5. Global Anticoagulants Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Atrial fibrillation
5.1.2. Atrial fibrillation causes life-threatening blood clots, stroke, or heart failure.
5.1.3. Deep vein thrombosis (DVT)
5.1.4. DVT have high risk due to overweight, heart failure, and varicose veins.
5.1.5. Ischemic stroke
5.1.6. Blood supply is inhibited to part of the brain due to blood clot.
5.1.7. Myocardial infarction (heart attack)
5.1.8. Change in lifestyle, and smoking increases risk of heart attack.
5.1.9. Pulmonary embolism
5.1.10. Technological advancement in healthcare
5.1.11. Others
6. Global Anticoagulants Market Analysis and Forecast, 2021-2031 By Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Oral anticoagulant
6.1.2. Injectable anticoagulant
7. North America Anticoagulants Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Anticoagulants Market Size and Forecast By Type
7.3. North America Anticoagulants Market Size and Forecast By Application
7.4. North America Anticoagulants Market Size and Forecast By Administration
7.5. U.S. Anticoagulants Market
7.5.1. Increasing Prevalence of Cancer in the Region Boosting the Market.
7.6. Canada Anticoagulants Market
7.6.1. Approval of Rivaroxaban to Prevent from Stroke, Myocardial Infarction, and Cardiovascular Death.
8. Europe Anticoagulants Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Anticoagulants Market Size and Forecast By Type
8.3. Europe Anticoagulants Market Size and Forecast By Application
8.4. Europe Anticoagulants Market Size and Forecast By Administration
8.5. UK Anticoagulants Market
8.5.1. Licensed to Use Warfarin, Apixaban, Dabigatran, Edoxaban and Rivaroxaban Oral Anticoagulants in the Region.
8.6. Germany Anticoagulants Market
8.6.1. Increasing Use of Anticoagulants in the Region.
8.7. France Anticoagulants Market
8.7.1. Increasing Need for Stroke Prevention with Atrial Fibrillation.
8.8. Rest of Europe Anticoagulants Market
9. Asia Pacific Anticoagulants Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Anticoagulants Market Size and Forecast By Type
9.3. Asia Pacific Anticoagulants Market Size and Forecast By Technology
9.4. Asia Pacific Anticoagulants Market Size and Forecast By Administration
9.5. China Anticoagulants Market
9.5.1. Excessive Tobacco and Alcohol Consumption.
9.6. India Anticoagulants Market
9.6.1. Increasing Demand for Vitamin K Antagonist (VKA) In the Region.
9.7. Japan Anticoagulants Market
9.7.1. Rising Ageing Population in The Region.
9.8. Rest of Asia Pacific Anticoagulants Market
10. Latin America Anticoagulants Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Anticoagulants Market Size and Forecast By Type
10.3. Latin America Anticoagulants Market Size and Forecast By Application
10.4. Latin America Anticoagulants Market Size and Forecast By Administration
10.4.1. Brazil Anticoagulants Market
10.4.1.1. Increasing Preference for Anticoagulants.
10.4.2. Mexico Anticoagulants Market
10.4.2.1. Prevalence of Cancer in the Region.
10.4.3. Rest of Latin America Anticoagulants Market
11. MEA Anticoagulants Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Anticoagulants Market Size and Forecast By Type
11.3. MEA Anticoagulants Market Size and Forecast By Application
11.4. MEA Anticoagulants Market Size and Forecast By Administration
11.5. South Africa Anticoagulants Market
11.5.1.1. High Incidence of Mortality Due to Cancer
11.6. Rest of MEA Anticoagulants Market
12. Companies in the Anticoagulants Market
12.1. Abbott Laboratories
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.3.2. Geographical Revenue, 2020
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Baxter International Inc.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. AstraZeneca plc
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Bayer AG
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Boehringer Ingelheim GmbH
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Eli Lilly and Company
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Bristol-Myers Squibb Company
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Merck & Co., Inc.
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Genentech Inc.
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. GlaxoSmithKline plc
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 2. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Anticoagulants Market Drivers & Restraints 2021
Table 7. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 13. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 18. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 23. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 28. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 38. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 43. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 48. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 53. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 59. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 60. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 61. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 62. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 63. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 64. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 65. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 66. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 67. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 68. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 69. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 70. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 71. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 72. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 73. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 74. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 75. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 76. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 77. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 78. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 79. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 80. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 81. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 82. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 83. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 84. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 85. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 86. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 87. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 88. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 89. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 90. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 91. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 92. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 93. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 94. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 95. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 96. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 97. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 98. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 99. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 100. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 101. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 102. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 103. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 104. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 105 North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 106. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 107. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 108. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 109. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 110. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 111. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 112. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 113. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 114. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 115. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 116. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR % CAGR %) (COVID - Scenario W)
Table 117. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 118. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 119. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 120. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table121. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 122. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 123. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 124. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 125. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 126. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 127. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 128. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 129. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 130. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 131. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 132. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 133. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 134. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 135. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 136. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 137. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 138. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 139. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 140. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 141. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 142. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 143. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 144. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 145. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 146. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 147. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 148. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 149. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 150. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR % CAGR %) (COVID - Scenario U)
Table 151. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR % CAGR %), (COVID - Scenario W)
Table 152. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 153. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 154. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 155. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 156. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 157. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 158. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 159. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 160. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 161. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 162. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 163. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 164. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 165. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 157. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185 Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192 Middle East Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193 Middle East Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Middle East Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209 Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 Leading 10 Anticoagulants Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 213. Abbott Laboratories Profile 2020 (CEO, HQ, Founded, Website)
Table 214. Abbott Laboratories Anticoagulants Selected Recent Contracts 2020 (Date, Program Type, Details)
Table 215. Abbott Laboratories Anticoagulants Product Offering (Segment, Product Offerings)
Table 216. Baxter International Inc Profile 2020 (CEO, HQ, Founded, Website)
Table 217. Baxter International Inc Anticoagulants Product Offering (Segment, Product Offerings)
Table 218. AstraZeneca plc Profile 2020 (CEO, HQ, Founded, Website)
Table 219. AstraZeneca plc Anticoagulants Selected Recent Contracts 2017-2020 (Date, Program Type, Details)
Table 220. AstraZeneca plc Anticoagulants Product Offering (Segment, Product Offerings)
Table 221. Bayer AG Profile 2020 (CEO, HQ, Founded, Website)
Table 222. Bayer AG Selected Recent Contracts 2015-2020 (Date, Program Type, Details)
Table 223. Bayer AG Anticoagulants Product Offering (Segment, Product Offerings)
Table 224. Boehringer Ingelheim GmbH Profile 2020 (CEO, HQ, Founded, Website)
Table 225 Boehringer Ingelheim GmbH Anticoagulants Product Offering (Segment, Product Offerings)
Table 226. Eli Lilly and Company Profile 2020 (CEO, HQ, Founded, Website)
Table 227. Eli Lilly and Company Anticoagulants Selected Recent Contracts 2015-2020 (Date, Program Type, Details)
Table 228 Eli Lilly and Company Anticoagulants Product Offering (Segment, Product Offerings)
Table 229. Bristol-Myers Squibb Company Profile 2020 (CEO, HQ, Founded, Website)
Table 230. Bristol-Myers Squibb Company Anticoagulants Product Offering (Segment, Product Offerings)
Table 231. Merck & Co., Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 232. Merck & Co., Inc. Anticoagulants Product Offering (Segment, Product Offerings)
Table 233. Genentech Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 234. Genentech Inc. Anticoagulants Product Offering (Segment, Product Offerings)
Table 235. GlaxoSmithKline plc Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 236. GlaxoSmithKline plc Total Company Sales 2015-2020 (US$M, AGR %)
Table 237. GlaxoSmithKline plc Product Offering (Segment, Product Offerings)
Table 238. Other Companies Involved in the Anticoagulants Market (Company, Location)
LIST OF FIGURES
Figure 1. Anticoagulants Market Type Overview
Figure 2. Anticoagulants Market By Type Overview
Figure 3. Anticoagulants Market By Application Overview
Figure 4. Anticoagulants Market By Administration Overview
Figure 5 Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M)
Figure 61. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M)
Figure 106. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M)
Figure 111. Asia-Pacific Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M)
Figure 141. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M)
Figure 146. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M)
Figure 151. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M)
Figure 161. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M)
Figure 166. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M)
Figure 171. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. Abbott Laboratories
2. Baxter International Inc.
3. AstraZeneca PLC
4. Bayer AG.
5. Boehringer Ingelheim GmbH
6. Eli Lilly and Company
7. Bristol-Myers Squibb Company
8. Merck & Co., Inc.
9. Genentech Inc.
10. GlaxoSmithKline PLC
11. Pfizer, Inc.
12. Sanofi S.A
13. Novartis AG
14. Daiichi Sankyo Company
15. Aspen Holdings
16. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
17. Portola Pharmaceuticals, Inc.
18. Lunac Therapeutics
19. The Medicines
20. United Therapeutics
21. Otsuka Pharmaceutical
22. Mitsubishi Tanabe Pharma Corporation
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Anticoagulants Market
2.1. Anticoagulants Market Definition
2.2. By Type Submarkets Definitions
2.3. By Application Submarkets Definitions
2.4. By Administration Submarkets Definitions
3. Anticoagulants Market Overview
3.1. Global Anticoagulants Market Size and Forecast by Region
3.2. Global Anticoagulants Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Geriatric Population
3.3.1.2. Rising prevalence of cancer
3.3.1.3. Global Healthcare Expenditure
3.3.1.4. Increasing cardiovascular disease & Diabetic Population.
3.3.1.5. Surging smoking & Obese Population.
3.3.2. Market Restraints/Challenges
3.3.2.1. Complication associated with use of oral anticoagulants.
3.3.2.2. High Cost
3.3.3. Opportunities
3.3.3.1. Increasing investment in R&D
3.3.3.2. Increasing FDA approval of anticoagulants drugs for clinical purpose.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Anticoagulants Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Vitamin K Antagonists (VKA)
4.1.2. VKA are group of substances which reduce the action of vitamin K and blood clotting.
4.1.3. Non-VKA Oral Anticoagulants (NOACs)
4.1.4. Rivaroxaban & fondaparinux works on Factor Xa inhibitor, which affects factor Xa within blood.
4.1.5. Heparin
4.1.6. Low-molecular-weight heparin (LMWH) such as dalteparin, enoxaparin, and tinzaparin, are given through subcutaneous injections.
4.1.7. others
5. Global Anticoagulants Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Atrial fibrillation
5.1.2. Atrial fibrillation causes life-threatening blood clots, stroke, or heart failure.
5.1.3. Deep vein thrombosis (DVT)
5.1.4. DVT have high risk due to overweight, heart failure, and varicose veins.
5.1.5. Ischemic stroke
5.1.6. Blood supply is inhibited to part of the brain due to blood clot.
5.1.7. Myocardial infarction (heart attack)
5.1.8. Change in lifestyle, and smoking increases risk of heart attack.
5.1.9. Pulmonary embolism
5.1.10. Technological advancement in healthcare
5.1.11. Others
6. Global Anticoagulants Market Analysis and Forecast, 2021-2031 By Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Oral anticoagulant
6.1.2. Injectable anticoagulant
7. North America Anticoagulants Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Anticoagulants Market Size and Forecast By Type
7.3. North America Anticoagulants Market Size and Forecast By Application
7.4. North America Anticoagulants Market Size and Forecast By Administration
7.5. U.S. Anticoagulants Market
7.5.1. Increasing Prevalence of Cancer in the Region Boosting the Market.
7.6. Canada Anticoagulants Market
7.6.1. Approval of Rivaroxaban to Prevent from Stroke, Myocardial Infarction, and Cardiovascular Death.
8. Europe Anticoagulants Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Anticoagulants Market Size and Forecast By Type
8.3. Europe Anticoagulants Market Size and Forecast By Application
8.4. Europe Anticoagulants Market Size and Forecast By Administration
8.5. UK Anticoagulants Market
8.5.1. Licensed to Use Warfarin, Apixaban, Dabigatran, Edoxaban and Rivaroxaban Oral Anticoagulants in the Region.
8.6. Germany Anticoagulants Market
8.6.1. Increasing Use of Anticoagulants in the Region.
8.7. France Anticoagulants Market
8.7.1. Increasing Need for Stroke Prevention with Atrial Fibrillation.
8.8. Rest of Europe Anticoagulants Market
9. Asia Pacific Anticoagulants Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Anticoagulants Market Size and Forecast By Type
9.3. Asia Pacific Anticoagulants Market Size and Forecast By Technology
9.4. Asia Pacific Anticoagulants Market Size and Forecast By Administration
9.5. China Anticoagulants Market
9.5.1. Excessive Tobacco and Alcohol Consumption.
9.6. India Anticoagulants Market
9.6.1. Increasing Demand for Vitamin K Antagonist (VKA) In the Region.
9.7. Japan Anticoagulants Market
9.7.1. Rising Ageing Population in The Region.
9.8. Rest of Asia Pacific Anticoagulants Market
10. Latin America Anticoagulants Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Anticoagulants Market Size and Forecast By Type
10.3. Latin America Anticoagulants Market Size and Forecast By Application
10.4. Latin America Anticoagulants Market Size and Forecast By Administration
10.4.1. Brazil Anticoagulants Market
10.4.1.1. Increasing Preference for Anticoagulants.
10.4.2. Mexico Anticoagulants Market
10.4.2.1. Prevalence of Cancer in the Region.
10.4.3. Rest of Latin America Anticoagulants Market
11. MEA Anticoagulants Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Anticoagulants Market Size and Forecast By Type
11.3. MEA Anticoagulants Market Size and Forecast By Application
11.4. MEA Anticoagulants Market Size and Forecast By Administration
11.5. South Africa Anticoagulants Market
11.5.1.1. High Incidence of Mortality Due to Cancer
11.6. Rest of MEA Anticoagulants Market
12. Companies in the Anticoagulants Market
12.1. Abbott Laboratories
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.3.2. Geographical Revenue, 2020
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Baxter International Inc.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. AstraZeneca plc
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Bayer AG
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Boehringer Ingelheim GmbH
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Eli Lilly and Company
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Bristol-Myers Squibb Company
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Merck & Co., Inc.
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Genentech Inc.
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. GlaxoSmithKline plc
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 2. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Anticoagulants Market Drivers & Restraints 2021
Table 7. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 13. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Vitamin K Antagonists (VKA) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 18. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Non-VKA Oral Anticoagulants (NOACs) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 23. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Heparin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 28. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Anticoagulants Submarket Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 38. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Atrial fibrillation Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 43. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Deep vein thrombosis (DVT) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 48. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Ischemic stroke Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 53. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Myocardial infarction (heart attack) Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 59. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 60. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 61. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 62. Pulmonary embolism Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 63. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 64. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 65. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 66. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 67. Others Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 68. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 69. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 70. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 71. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 72. Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 73. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 74. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 75. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 76. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 77. Oral anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 78. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 79. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 80. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 81. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 82. Injectable anticoagulant Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 83. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 84. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 85. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 86. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 87. Regional Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 88. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 89. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 90. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 91. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 92. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 93. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 94. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 95. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 96. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 97. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 98. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 99. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 100. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 101. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 102. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 103. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 104. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 105 North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 106. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 107. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 108. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 109. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 110. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 111. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 112. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 113. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 114. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 115. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 116. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR % CAGR %) (COVID - Scenario W)
Table 117. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 118. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 119. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 120. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table121. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 122. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 123. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 124. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 125. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 126. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 127. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 128. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 129. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 130. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 131. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 132. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 133. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 134. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 135. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 136. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 137. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 138. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 139. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 140. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 141. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 142. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 143. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 144. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 145. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 146. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 147. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 148. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 149. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 150. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR % CAGR %) (COVID - Scenario U)
Table 151. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR % CAGR %), (COVID - Scenario W)
Table 152. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 153. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 154. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 155. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 156. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 157. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 158. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 159. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 160. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 161. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 162. Asia Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 163. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 164. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 165. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Asia Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Asia Pacific Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 157. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Asia Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. RoAPAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185 Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192 Middle East Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193 Middle East Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Middle East Anticoagulants Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209 Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 Leading 10 Anticoagulants Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 213. Abbott Laboratories Profile 2020 (CEO, HQ, Founded, Website)
Table 214. Abbott Laboratories Anticoagulants Selected Recent Contracts 2020 (Date, Program Type, Details)
Table 215. Abbott Laboratories Anticoagulants Product Offering (Segment, Product Offerings)
Table 216. Baxter International Inc Profile 2020 (CEO, HQ, Founded, Website)
Table 217. Baxter International Inc Anticoagulants Product Offering (Segment, Product Offerings)
Table 218. AstraZeneca plc Profile 2020 (CEO, HQ, Founded, Website)
Table 219. AstraZeneca plc Anticoagulants Selected Recent Contracts 2017-2020 (Date, Program Type, Details)
Table 220. AstraZeneca plc Anticoagulants Product Offering (Segment, Product Offerings)
Table 221. Bayer AG Profile 2020 (CEO, HQ, Founded, Website)
Table 222. Bayer AG Selected Recent Contracts 2015-2020 (Date, Program Type, Details)
Table 223. Bayer AG Anticoagulants Product Offering (Segment, Product Offerings)
Table 224. Boehringer Ingelheim GmbH Profile 2020 (CEO, HQ, Founded, Website)
Table 225 Boehringer Ingelheim GmbH Anticoagulants Product Offering (Segment, Product Offerings)
Table 226. Eli Lilly and Company Profile 2020 (CEO, HQ, Founded, Website)
Table 227. Eli Lilly and Company Anticoagulants Selected Recent Contracts 2015-2020 (Date, Program Type, Details)
Table 228 Eli Lilly and Company Anticoagulants Product Offering (Segment, Product Offerings)
Table 229. Bristol-Myers Squibb Company Profile 2020 (CEO, HQ, Founded, Website)
Table 230. Bristol-Myers Squibb Company Anticoagulants Product Offering (Segment, Product Offerings)
Table 231. Merck & Co., Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 232. Merck & Co., Inc. Anticoagulants Product Offering (Segment, Product Offerings)
Table 233. Genentech Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 234. Genentech Inc. Anticoagulants Product Offering (Segment, Product Offerings)
Table 235. GlaxoSmithKline plc Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 236. GlaxoSmithKline plc Total Company Sales 2015-2020 (US$M, AGR %)
Table 237. GlaxoSmithKline plc Product Offering (Segment, Product Offerings)
Table 238. Other Companies Involved in the Anticoagulants Market (Company, Location)
LIST OF FIGURES
Figure 1. Anticoagulants Market Type Overview
Figure 2. Anticoagulants Market By Type Overview
Figure 3. Anticoagulants Market By Application Overview
Figure 4. Anticoagulants Market By Administration Overview
Figure 5 Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Anticoagulants Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Anticoagulants Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Anticoagulants Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Anticoagulants Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Anticoagulants Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Anticoagulants Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Anticoagulants Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M)
Figure 61. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M)
Figure 106. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Anticoagulants Market Forecast By Application 2021-2031 (US$M)
Figure 111. Asia-Pacific Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Anticoagulants Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M)
Figure 141. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M)
Figure 146. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M)
Figure 151. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M)
Figure 161. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Anticoagulants Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M)
Figure 166. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Anticoagulants Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M)
Figure 171. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Anticoagulants Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Anticoagulants Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. Abbott Laboratories
2. Baxter International Inc.
3. AstraZeneca PLC
4. Bayer AG.
5. Boehringer Ingelheim GmbH
6. Eli Lilly and Company
7. Bristol-Myers Squibb Company
8. Merck & Co., Inc.
9. Genentech Inc.
10. GlaxoSmithKline PLC
11. Pfizer, Inc.
12. Sanofi S.A
13. Novartis AG
14. Daiichi Sankyo Company
15. Aspen Holdings
16. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
17. Portola Pharmaceuticals, Inc.
18. Lunac Therapeutics
19. The Medicines
20. United Therapeutics
21. Otsuka Pharmaceutical
22. Mitsubishi Tanabe Pharma Corporation
Companies Profiled in the Report
1. Abbott Laboratories
2. Baxter International Inc.
3. AstraZeneca PLC
4. Bayer AG.
5. Boehringer Ingelheim GmbH
6. Eli Lilly and Company
7. Bristol-Myers Squibb Company
8. Merck & Co., Inc.
9. Genentech Inc.
10. GlaxoSmithKline PLC
11. Pfizer, Inc.
12. Sanofi S.A
13. Novartis AG
14. Daiichi Sankyo Company
List of Companies Mentioned in the Report:
1. Abbott Laboratories
2. Baxter International Inc.
3. AstraZeneca PLC
4. Bayer AG.
5. Boehringer Ingelheim GmbH
6. Eli Lilly and Company
7. Bristol-Myers Squibb Company
8. Merck & Co., Inc.
9. Genentech Inc.
10. GlaxoSmithKline plc
11. Pfizer, Inc.
12. Sanofi S.A
13. Novartis AG
14. Daiichi Sankyo Company
15. Aspen Holdings
16. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
17. Portola Pharmaceuticals, Inc.
18. Lunac Therapeutics
19. The Medicines
20. United Therapeutics
21. Otsuka Pharmaceutical
22. Mitsubishi Tanabe Pharma Corporation
List of Organizations Mentioned in the Report
1. World Health Organization
2. The European Medicines Agency (EMA)
3. The American Association for Cancer Research.
4. Organic Process Research & Development
5. The National Cancer Survivorship Resource Center
6. US Food & Drug Administration
7. US National Library of Medicine
8. National Institutes of Health
9. National Association for Biomedical Research
10. Center for Disease Control and Prevention CDC
11. Journal of the American college of Cardiology
12. National Association of Orthopaedic Nurses
13. National Foundation for Infectious Diseases.
14. Clinical Infectious Diseases
15. American Association for Cancer Research.
16. Center for Diseases Dynamics, Economics & Policy (CDDEP)
17. The American Society of Hematology in Orlando
18. The Global Health Security Agenda (GHSA)
19. American Cancer Society.
20. World Cancer Research Fund
21. National Cancer Institute
1. Abbott Laboratories
2. Baxter International Inc.
3. AstraZeneca PLC
4. Bayer AG.
5. Boehringer Ingelheim GmbH
6. Eli Lilly and Company
7. Bristol-Myers Squibb Company
8. Merck & Co., Inc.
9. Genentech Inc.
10. GlaxoSmithKline PLC
11. Pfizer, Inc.
12. Sanofi S.A
13. Novartis AG
14. Daiichi Sankyo Company
List of Companies Mentioned in the Report:
1. Abbott Laboratories
2. Baxter International Inc.
3. AstraZeneca PLC
4. Bayer AG.
5. Boehringer Ingelheim GmbH
6. Eli Lilly and Company
7. Bristol-Myers Squibb Company
8. Merck & Co., Inc.
9. Genentech Inc.
10. GlaxoSmithKline plc
11. Pfizer, Inc.
12. Sanofi S.A
13. Novartis AG
14. Daiichi Sankyo Company
15. Aspen Holdings
16. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
17. Portola Pharmaceuticals, Inc.
18. Lunac Therapeutics
19. The Medicines
20. United Therapeutics
21. Otsuka Pharmaceutical
22. Mitsubishi Tanabe Pharma Corporation
List of Organizations Mentioned in the Report
1. World Health Organization
2. The European Medicines Agency (EMA)
3. The American Association for Cancer Research.
4. Organic Process Research & Development
5. The National Cancer Survivorship Resource Center
6. US Food & Drug Administration
7. US National Library of Medicine
8. National Institutes of Health
9. National Association for Biomedical Research
10. Center for Disease Control and Prevention CDC
11. Journal of the American college of Cardiology
12. National Association of Orthopaedic Nurses
13. National Foundation for Infectious Diseases.
14. Clinical Infectious Diseases
15. American Association for Cancer Research.
16. Center for Diseases Dynamics, Economics & Policy (CDDEP)
17. The American Society of Hematology in Orlando
18. The Global Health Security Agenda (GHSA)
19. American Cancer Society.
20. World Cancer Research Fund
21. National Cancer Institute
Download sample pages
Complete the form below to download your free sample pages for Anticoagulants Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Anticoagulants Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
